Bullfrog AI Holdings Inc (NASDAQ:BFRG) shares are moving higher Wednesday after the company reported early results from its collaboration with Lieber Institute for Brain Development (LIBD).

What To Know: The proprietary data from LIBD includes gene expression data from over 2,800 brain samples encompassing schizophrenia, bipolar disorder, major depressive disorder and non-psychiatric control brains.

BullFrog AI said it clustered subjects based solely on their biological data using graph analytics, which provided “promising insights” and highlighted the distinct differences and similarities in biological pathways across various brain disorders.

“This collaboration marks a pivotal moment in psychiatric research. By employing our bfLEAP™ platform on LIBD’s unrivaled brain data, we’ve gained invaluable ground into unraveling the biological underpinnings of psychiatric disorders,” said Vin Singh, CEO of BullFrog AI.

“These preliminary findings have the potential to not only deepen our understanding but also pave the way for developing more targeted and effective treatments that set the stage for us to seek out revenue-generating strategic partnerships with pharmaceutical companies.”

BullFrog AI is a technology-enabled drug development company using AI and machine learning to enable the successful development of pharmaceuticals and biologics. 

Check This Out: Alibaba Shares Tumble Wednesday – Here’s Why

BFRG Price Action: BullFrog AI shares were up 27.8% at $3.37 at the time of publication, according to Benzinga Pro.

Photo: Temel from Pixabay.